Enchondroma
Overview
• Enchondroma is a benign hyaline cartilage tumor, accounting for 20-25% of benign bone tumors.
• It arises from residual cartilage cells that fail to undergo necrosis after physeal growth.
• Can be solitary or multiple (Ollier’s disease, Maffucci syndrome).
Clinical Presentation
Often asymptomatic, detected incidentally (except in hand lesions).
Hand enchondromas: Pain due to bone expansion, cortical thinning, or microfractures.
Long bone enchondromas with pain: Rule out first intra-articular pathologies, atypical cartilage tumor or chondrosarcoma
Associated Syndromes
Ollier’s disease: Multiple enchondromas, unilateral, 20-50% malignant transformation risk. Lesions are generally unilateral. Short stature, limb length discrepancy, and angular deformities in bones and joints are commonly seen.
Maffucci syndrome: Enchondromas + soft tissue hemangiomas; higher malignancy risk than Ollier’s. Due to phleboliths, hemangiomas are also detected on X-rays.
Common Sites
Hands (40-65%): Proximal phalanges > metacarpals > middle phalanges.
Long bones: Femur, humerus, tibia (metaphyseal).
Rare in carpal/tarsal bones or distal phalanges.
Imaging Features
X-ray:
Hands: Lytic, sclerotic rim, bone expansion, cortical thinning, calcification is not usually seen.
Long bones: Metaphyseal, indistinct margins, endosteal scalloping, matrix calcification.
CT: Evaluates calcification and cortical integrity.
MRI: Assesses soft tissue extension, peritumoral edema, contrast enhancement (for differential diagnosis) and fat entrapment.
PET-CT: Useful for enchondromatosis/pelvic lesions
Biopsy
Not routine; reserved for atypical features (e.g., pain, growth, or imaging suspicious for chondrosarcoma).
Target less calcified, fat entrapment and heterogeneous areas on MRI. Biopsy tract should align with potential surgical incision.
Treatment
Asymptomatic, small (<4 cm), stable lesions: Annual monitoring.(BACTIP Protocole* : Birmingham Atypical Cartilage Tumor Imaging Protocol)
Surgical indications:
Pain, growth on follow-up, or pathologic fracture risk.
Techniques: Intralesional curettage + adjuvant + bone-filler (PMMA/graft) ± fixation (fracture risk in lower extremities).
Hand lesions: Curettage alone/ Curettage and bone filler (PMMA/Graft)
Differential Diagnosis
Atypical Cartilage Tumor (ACT):
WHO 2020 reclassified grade I chondrosarcomas in extremities as ACT (no metastasis risk but can recur).
Suspect if pain, size >4 cm, generalized endosteal scalloping.
Chondrosarcoma:
Cortical destruction, soft tissue involvement, axial skeleton location.
Type | Tumor Length | Endosteal Scalloping | Management |
1a | <4 cm | None | Discharge |
1b | <4 cm | Focal | Follow-up in 3 years; refer to oncology or discharge based on changes |
1c | <4 cm | Generalized | Immediate oncology referral |
2a | ≥4 cm | None | Follow-up in 3 years; refer to oncology or discharge based on changes |
2b | ≥4 cm | Focal | Follow-up at 1 & 3 years; refer to oncology or discharge |
2c | ≥4 cm | Generalized | Immediate oncology referral |
3 | any size | Aggressive features | Immediate oncology referral |
The Birmingham Atypical Cartilage Tumor Imaging Protocol (BACTIB) classification